West Pharmaceutical Services (WST) DIvidends Date & History

Key Takeaways

• West Pharmaceutical Services (WST) offers a modest current dividend yield of 0.32% with a forward annual payout of $0.88 per share, paid quarterly at $0.22.
• The company boasts a 34-year consecutive dividend increase streak, marking it as a reliable dividend growth stock.
• Extremely low payout ratio of 12.52% underscores exceptional sustainability, supported by robust earnings and free cash flow (FCF).
• 2025 FCF reached $468.9 million, providing over 7x coverage of annual dividends.
• Upcoming ex-dividend date is April 29, 2026, with payment on May 6, 2026.
• Yield trails medical device peers like MDT (3.3%) and SYK (1.0%), reflecting WST's growth-oriented profile.

Dividend Overview

West Pharmaceutical Services (WST), a leader in injectable drug packaging and delivery systems, maintains a modest dividend policy suited to its growth profile in the medical instruments sector. The current forward annual dividend stands at $0.88 per share, yielding approximately 0.32% based on recent stock prices around $275. Payments occur quarterly, with the next installment of $0.22 scheduled for payment on May 6, 2026, following an ex-dividend date of April 29, 2026. This positions WST as a dividend growth stock rather than a high-yield play, prioritizing reinvestment in expansion while rewarding long-term shareholders with steady increases.

Dividend History and Growth

WST has a commendable track record of dividend consistency, with 34 consecutive years of increases as of recent data. The company has raised its payout five times over the past five years, achieving a compound annual growth rate (CAGR) of about 5.5%. Quarterly dividends have grown from lower bases in prior decades, reflecting a long-term strategy of balancing shareholder returns with operational investments. No cuts have occurred in this extended streak, underscoring management's commitment to progressive dividend policy amid expanding demand for its specialized pharmaceutical components.

Dividend Sustainability and Payout Ratio

The sustainability of WST's dividend is rock-solid, evidenced by a trailing payout ratio of just 12.52%—meaning only a fraction of earnings is distributed, leaving ample room for growth and resilience. Earnings per share comfortably cover the dividend multiple times over, complemented by strong profitability metrics like a 16.06% profit margin and 16.85% return on equity (ROE). Free cash flow (FCF) hit $468.9 million in 2025, dwarfing the estimated $63 million in total annual dividends and providing over 7x coverage. Low debt levels and $754.8 million in operating cash flow further bolster confidence in ongoing payments, even through economic cycles.

Dividend Compared to Industry Peers

In the medical devices and instruments industry, WST's 0.32% yield is notably lower than key peers, signaling its emphasis on reinvestment over immediate income. For instance, Medtronic (MDT) offers around 3.3%, Stryker (SYK) about 1.0%, and Becton Dickinson (BDX) roughly 1.5%. While peers provide higher yields, WST's superior growth streak and ultra-low payout ratio appeal to investors prioritizing future appreciation alongside dividends in a sector dominated by innovation-driven firms.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener today to streamline your research.

Is This Stock Attractive for Dividend Investors?

West Pharmaceutical Services (WST) suits dividend growth investors who prioritize longevity and safety over high current yields. Its 34-year streak of increases and minuscule 12.52% payout ratio make it ideal for those building portfolios around compounding returns from quality compounders in healthcare. Conservative long-term holders may appreciate the robust FCF coverage and financial stability, which mitigate risks in a cyclical sector. However, income-focused investors seeking 3%+ yields might look elsewhere, as WST's modest 0.32% payout better complements total return strategies. Growth-oriented dividend enthusiasts will value its balance of modest income and potential for future hikes amid strong industry tailwinds like biologics demand.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations